News

AbbVie unit wins $56 mln in US patent trial against Botox rival
A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...
Orange County Business Journal4d
Allergan Awarded $56M Verdict Against Revance
A federal jury in Delaware found that Revance's rival product infringed patents for Allergan's market-leading neurotoxin ...
Fierce Pharma4d
AbbVie wins $56M royalty award from Revance in Botox patent infringement case
AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...
Crain's Chicago Business5d
AbbVie's Allergan wins $56 million in Botox patent fight
A federal jury July 18 said Revance Therapeutics' skin medication infringed on patents for anti-wrinkle treatment Botox and owes AbbVie-owned Allergan $56 million.
Topeka business is helping clients with non-surgical skin and facial rejuvenation
Owner of Topeka's Pivot Aesthetics emphasizes the importance of preventative care in maintaining skin health and integrity ...
Nasdaq4d
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs ...
Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc, Dysport, Xeomin, Jeuveau, Daxxify, or ...
Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings
Evolus is demonstrating strong market share gains, successful new product launches, and reaffirmed 2025 revenue guidance despite recent share price volatility. Read the stock analysis here.
Morningstar4d
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's ... - Morningstar
Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc, Dysport, Xeomin, Jeuveau, Daxxify, or ...